Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Filing Names

Medimmune Llc
Medimmune Llc_20131212

Medimmune Llc patents

Recent patent applications related to Medimmune Llc. Medimmune Llc is listed as an Agent/Assignee. Note: Medimmune Llc may have other listings under different names/spellings. We're not affiliated with Medimmune Llc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medimmune Llc-related inventors

An improved manufacturing method

This application is directed to a method of producing vials containing a composition comprising a recombinant protein. In some embodiments, the method comprises: (a) providing a container containing a composition comprising a recombinant protein optionally where the container has been stored under positive pressure; (b) applying a vacuum to the... Medimmune Llc

Cd40l-fc fusion polypeptides and methods of use thereof

Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).... Medimmune Llc

Method of conjugating a polypeptide

with a polypeptide comprising at least one thiol group and molecules obtained from said method.... Medimmune Llc

Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

Provided herein are compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-L1 antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided.... Medimmune Llc

Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties

The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG, constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgGI, e.g., human IgGI), that have modifications... Medimmune Llc

Cell culture methods and media comprising n-acetylcysteine

This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.... Medimmune Llc

Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof

This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV bispecific binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.... Medimmune Llc

Antibody scaffold for homogenous conjugation

Provided in some embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain. Also provided in certain embodiments are antibodies comprising... Medimmune Llc

Antibody formulation

Herein described as liquid formulations of antibodies and biologically active fragments thereof that specifically bind to human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.... Medimmune Llc

Method for purifying active polypeptides or immunoconjugates

The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising... Medimmune Llc

Treatment of polybacterial infections

Provided herein are methods of preventing and treating polybacterial infections comprising administering an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope produced by at least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds to Staphylococcus aureus... Medimmune Llc

Alpha-v beta-8 antibodies

Provided herein are antibodies specific for integrin αvβ8 that change the conformation of β8 so that, upon binding the ability of αvβ8 to induce release of active, mature TGFβ peptide is inhibited.... Medimmune Llc

Interferon alpha-induced pharmacodynamic markers and uses thereof

The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder,... Medimmune Llc

Multispecific and multivalent binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using... Medimmune Llc

Single-use, self destructing shield for syringe needle

Disclosed are embodiments of a cap covering a needle on a syringe. The cap in the closed configuration is sized and dimensioned to cover the needle, and after the cap is removed from the needle the cap assumes an open configuration that is not readily usable to re-cap the needle.... Medimmune Llc

Methods for treating chronic obstructive pulmonary disease using benralizumab

Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.... Medimmune Llc

Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy

The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.... Medimmune Llc

Mrka polypeptides, antibodies, and uses thereof

The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a... Medimmune Llc

Stable anti-ifnar1 formulation

The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically... Medimmune Llc

Compositions and methods for modulating and redirecting immune responses

Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and T cells are contacted with 1, 2, or more immune checkpoint antagonists... Medimmune Llc

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Medimmune Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medimmune Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by